BRETEC — Bioretec Oy Share News
0.000.00%
Last trade - 00:00- €28.71m
- €16.69m
- €3.52m
Brief: Bioretec Q1 EBITDA EUR -1.112 Million
Brief: Bioretec's RemeOs Biodegradable Magnesium Alloy Composition Has Been Allowed A Patent By U.S. Patent Office
Brief: Bioretec Gets FDA Breakthrough Device Designation Status For Remeos Spinal Interbody Cage
Brief: Bioretec Oy Says European Market Authorization Application Of RemeOs Trauma Screw Has Progressed To Expert Panel Stage
Brief: Bioretec FY EBITDA EUR -2.833 Million
Brief: Bioretec: Board To Initiate New CEO Recruitment Process
Brief: Bioretec Estimates That The European Market Authorization Approval For The Biodegradable Remeos™ Trauma Screw Will Move To Q1, 2024
Brief: Bioretec Enters Into U.S. Distribution Agreement With Spartan Medical For RemeOs Screws
Brief: Bioretec Receives Research And Development Grant
Brief: Bioretec Aims For Net Sales Of EUR 62 Mln By End-2027
Brief: Bioretec Oy Invests In CNC Machining Center To Increase Remeos Production Capacity
Brief: Bioretec Invests In CNC Machining Center To Increase RemeOsTM Capacity
Brief: Bioretec Says Subscription Price Of Placing Shares Is EUR 2 Per Placing Share
Brief: Bioretec Initiates Private Placement
Brief: Bioretec Updates Its Product Pipeline To Accelerate Commercialization Strategy
Brief: Bioretec Receives FDA Approval For Bioresorbable Metal Product
Brief: Bioretec Says FDA Approves Co's Remeos Trauma Screw As First Bioresorbable Metal Implant In U.S. Market
Brief: Bioretec Board To Reschedule Date Of AGM, Projected Date Is May 26, 2023
Brief: Bioretec H2 Net Loss Narrows To EUR 1.0 Mln